Kymera Therapeutics (KYMR) Morgan Stanley 24th Annual Global Healthcare Conference summary

Strategic focus and platform evolution

• Targeted protein degradation leverages the ubiquitin-proteasome system to address undrugged disease-causing proteins, with a shift in recent years to focus almost exclusively on immunology.

• Key learnings from IRAK4 program include the importance of specificity, dose selection, and molecule distribution, leading to improved second-generation degraders.

• Partnerships with Sanofi (immunology) and Gilead (oncology) complement a pipeline of wholly owned programs, including STAT6 and IRF5 degraders.

Pipeline highlights and clinical progress

• KT-485, a second-generation IRAK4 degrader, is in phase I with a creative study design including healthy volunteers and HS patients, focusing on proof of mechanism.

• KT-621, an oral STAT6 degrader, targets a large unmet need in moderate to severe atopic dermatitis, with potential to expand the market beyond injectable biologics.

• Phase Ib data for KT-621 showed complete STAT6 degradation in blood and tissue, with biomarker and disease activity improvements aligning with advanced T2 biologics.

• BROADEN2 phase IIb study for KT-621 is enrolling rapidly, with high patient and investigator interest, and aims to confirm efficacy and safety for first-line, post-topical use.

• KT-579, an oral IRF5 degrader, is prioritized for lupus with phase I data expected in Q4, aiming to demonstrate safe degradation and biological replication in humans.

Market opportunity and clinical differentiation

• Only about 5% of moderate to severe atopic dermatitis patients are on advanced systemic therapy, highlighting a significant opportunity for safe, effective oral treatments.

• KT-621 is positioned to expand patient access and market size, potentially serving as the first-line oral therapy post-topical treatment.

• Clinical endpoints for KT-621 focus on EASI-75, IGA 0/1, and itch reduction, with biomarkers supporting the mechanistic story but not as primary outcomes.

• BROADEN2 data is expected to de-risk other Type 2 indications, with read-through anticipated for dermatology, GI, and respiratory diseases.